RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

Journal of Clinical Oncology

Volumn 29, Issue 32, 2011, Pages 4286-4293

  Brufsky, Adam M ^a   Hurvitz, Sara ^b   Perez, Edith ^e   Swamy, Raji ^c   Valero, Vicente ^f   O'Neill, Vincent ^c   Rugo, Hope S ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; NAB PACLITAXEL; NAVELBINE; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND DEHISCENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 81155123190     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.1255     Document Type: Article

References (16)

1. Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
2. Gray R, Bhattacharya S, Bowden C, et al.: Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27:4966-4972, 2009
3. Miles DW, Chan A, Dirix LY, et al.: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010
4. Robert NJ, Diéras V, Glaspy J, et al.: RIBBON-1: Randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
5. Albain KS, Nag SM, Calderillo-Ruiz G, et al.: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26: 3950-3957, 2008
6. Chan S, Romieu G, Huober J, et al.: Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753-1760, 2009
7. Hamilton A, Hortobagyi G: Chemotherapy: What progress in the last 5 years? J Clin Oncol 23:1760-1775, 2005 (Pubitemid 46211428)
8. National Comprehensive Cancer Network (NCCN): Breast Cancer V. 2.2010, NCCN Clinical Practice Guidelines in Oncology, 2010
9. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
10. Miller KD, Chap LI, Holmes FA, et al.: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
11. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
12. GlaxoSmithKline: Tykerb (lapatinib) prescribing information. Research Triangle Park, NC, GlaxoSmithKline, 2010. http://us.gsk.com/products/assets/us- tykerb.pdf
13. Bristol-Meyers Squibb: Ixempra (ixabepilone) prescribing information. Princeton, NJ, Bristol-Meyers Squibb, 2010. http://packageinserts.bms.com/pi/pi- ixempra.pdf
14. Martín M, Ruiz A, Muñoz M, et al.: Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Reseaarch Group (GEICAM) trial. Lancet Oncol 8:219-225, 2007 (Pubitemid 46291704)
15. Venturino A, Comandini D, Simoni C, et al.: Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. Breast Cancer Res Treat 60:195-200, 2000 (Pubitemid 30440534)
16. Weber BL, Vogel C, Jones S, et al.: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730, 1995